Table 1.

Patient characteristics and clinical results

Pt #Age, ySexMelanoma originDisease sitesStageClone specificityTCR Vβ clonotypeInfused clones (n, ×109)IL2 dosesAutoimmunityTumor response30-d clone persistence (% CD8+Tet++)
GP156MCutaneousLu, LNM1bgp1006.545.112RashNR4.1
GP260MOcularLiM1cgp1007.60.49RashNR0.9
GP356MCutaneousLNM1agp1007.633.14RashNR3.1
GP451MOcularLiM1cgp1007.622.27RashNR2.4
GP555FMucosalLu, Li, SQ, LNM1cgp10029.118.87RashNR<0.1
GP634FCutaneousSQ, LN, brainM1cgp10012.310.89NoneNR<0.1
GP762MMucosalLuM1bgp1007.61.59RashNR<0.1
GP855MOcularLu, LiM1cgp1007.60.16RashNR<0.1
GP966MMucosalAdrenal, SQ, LN, BMM1cgp10091.56NoneNR<0.1
GP1045MCutaneousSQ, LNM1agp1004.19.57RashNR0.7
M165FCutaneousCut, SQ, LNM1aMART7.31.50RashNR<0.1
M245MCutaneousBrain, Lu, Li, LN, STM1cMART4.1/24.121.4/8.70VitiligoNR0.3/6.5
M335MMucosalLu, Li, BoneM1cMART24.30NoneNR<0.1
M452FCutaneousLu, LNM1bMART4.358.30RashNR7.8
M542MCutaneousLu, Li, bone, LNM1cMART2815.10NoneNR3.8

Abbreviations: BM, bone marrow; Cut, cutaneous; F, female; Li, liver; LN, lymph node; Lu, lung; M, male; NR, nonresponse; SQ, subcutaneous.